nabu.science
MethodologyAboutContact

 

Reliability concern: This paper was retracted on 2024-06-24. See notice: 10.1038/s41586-024-07691-8.

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-ADA5613D·Framework v5.5·Pipeline v0.4·Evaluated 07 Aug 2026·OECD: 3.3 Neurology and psychiatry·Subfield: Physiology·Basis: Full text·Type: Laboratory experiment

RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory

Sylvain Lesné et al.Sylvain Lesné, Ming Teng Koh, Linda Kotilinek et al.·2006·10.1038/nature04533 ↗

Primary claim

memory deficits in middle-aged Tg2576 mice are caused by the extracellular accumulation of a 56-kDa soluble amyloid-β assembly, which we term Ab*56

Tentative · mouse evidence is correlational, with causality inferred indirectly from rat infusion
In brief

A field-shaping oligomer study linking Aβ*56 to memory impairment, constrained by indirect endogenous causality.

ReliabilityConcerns4 of 4 checks completeRead the 3 entries ↓
Abstract not available — view at DOI ↗

Key Claims

Primary finding · Tentative

memory deficits in middle-aged Tg2576 mice are caused by the extracellular accumulation of a 56-kDa soluble amyloid-β assembly, which we term Ab*56

mouse evidence is correlational, with causality inferred indirectly from rat infusion

Abstract; Results, Figs. 1, 3, 4
Secondary · Supported

Ab*56 purified from the brains of impaired Tg2576 mice disrupts memory when administered to young rats

rat probe-trial impairment with acquisition and visible-platform controls

Abstract; Results, Fig. 4b–e
Secondary · Supported

the 56-kDa assembly correlating substantially better than the 40-kDa assembly

reported inverse correlations favor 56-kDa but 40-kDa also correlates

Results, Fig. 3g–h
Secondary · Supported

Ab*56 impairs memory independently of plaques or neuronal loss

timing before abundant plaques and model context support plaque-independent impairment within Tg2576

Abstract; Introduction; Results, Fig. 1
Secondary · Tentative

trimers are the fundamental Ab assembly unit in vivo

inferred from denaturation and migration patterns rather than direct structural determination

Results, Fig. 2a–c

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Specific candidate for soluble Aβ toxicity

The article moves from a broad soluble-oligomer hypothesis to a named 56-kDa assembly with temporal emergence at the memory-decline window and stronger correlation with impairment than the 40-kDa band. This gives the field a concrete candidate rather than a general class of species.

↳ Results, Figs. 1c and 3g–h

#methodological rigour

Multi-method biochemical characterization strategy

Aβ*56 is assessed with multiple antibodies, denaturation behavior, size-exclusion chromatography, silver staining, and mass spectrometry as summarized in the main text. These methods reduce the likelihood that the 56-kDa band is simply APP, an APP cleavage product, or an SDS-PAGE artifact.

↳ Results, Fig. 2; Results, Fig. 4a

#methodological rigour

Behavioral controls distinguish retention impairment

The rat experiment reports no effect on hidden-platform acquisition or visible-platform performance, while the probe test shows impaired spatial bias after Aβ*56 infusion. The ten-day retest without infusion is presented as evidence against lasting debilitation.

↳ Results, Fig. 4b–e; Supplementary Fig. 6 described in Results

Limitations

#contribution

Endogenous causality remains indirectly tested

The paper’s strongest claim is that Aβ*56 causes memory decline in middle-aged Tg2576 mice, but the Tg2576 evidence is temporal and correlational. The causal experiment shows that exogenous purified Aβ*56 can impair memory in rats, not that endogenous Aβ*56 is necessary or sufficient in Tg2576 mice.

↳ Abstract; Results before and after Fig. 4

#methodological rigour

Infusion dose lacks physiological benchmark

The rat study infuses 10 µl of 0.85 mM Aβ*56, but the article does not benchmark this exposure against endogenous Aβ*56 concentrations in Tg2576 brain. That gap limits interpretation of how closely the rat experiment models the endogenous mouse condition.

↳ Methods, Behavioral tests; Results, Fig. 4

#methodological rigour

Animal ethics statement is absent

The supplied text describes transgenic mouse testing, rat cannula implantation, and intracerebroventricular infusion, but it does not include an explicit animal ethics approval statement. This is recorded as a conduct note rather than a severe reliability concern, given the publication era and absence of a visible protocol violation.

↳ Methods, Behavioral tests; Author Information

Does this match your read? Add your assessment ↓

Withdrawn — shown for reference only

Nabu Commentary

The strongest part of the article is its integrated evidential chain: temporal emergence of Aβ assemblies, correlations with spatial memory, biochemical characterization, and acute behavioral testing of purified Aβ*56. The main limitation is that the paper’s endogenous causal conclusion rests on correlation in Tg2576 mice plus sufficiency-like evidence from rat infusion, without selective removal or blockade of Aβ*56 in the mouse model. Methodological concerns around the rat sample size, infusion concentration, and supplement-dependent purification details keep Methodological Rigour below the highest range. Impact potential remains meaningful because the paper proposes a specific diagnostic and therapeutic target, but transferability is limited by the absence of human or multi-model validation.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.7±0.2

Contribution
3.8

The score reflects a substantial 2006 contribution: the paper identifies a specific soluble Aβ assembly, links it temporally and correlationally to memory decline, and tests purified material in rats. It is not scored higher because the headline causal claim about endogenous Tg2576 memory decline is stronger than the direct within-model evidence.

Abstract; Results, Figs. 1–4

“memory deficits in middle-aged Tg2576 mice are caused by the extracellular accumulation”

Methodological Rigour
3.5

The study combines age-stratified biochemical profiling, antibody validation, size-exclusion chromatography, correlation analysis, and a controlled rat infusion experiment. Methodological Rigour is limited by modest rat sample size, lack of selective endogenous Aβ*56 manipulation, unbenchmarked infusion concentration, and key purification details placed in Supplementary Methods.

Methods, Behavioral tests; Results, Figs. 2–4

“Ten rats received Ab*56 and another ten received vehicle”

Reporting
3.9

The argument is easy to follow from the Tg2576 paradox, to candidate selection criteria, to biochemical characterization, to behavioral testing. The main clarity limitation is precision: the paper acknowledges correlation before the rat experiment, but the Abstract and conclusion use stronger causal wording.

Results before Fig. 4; Abstract; concluding Results paragraph

“so far our data on the relationship between Ab*56 and memory impairment are correlative”

Positioning
3.7

The paper is grounded in prior work on Tg2576 mice, soluble Aβ assemblies, intracellular Aβ, and plaque-independent dysfunction. Positioning is limited by relatively brief treatment of alternative soluble oligomer species and model-specific uncertainty around translating Aβ*56 to human Alzheimer’s disease.

Introduction; Results discussing Supplementary Figs. 4–5; Discussion

“the identity of the theoretical intermediates has been elusive”

Reliability

Concerns4 of 4 checks


Internal CoherenceNoted

The experimental narrative is internally coherent, moving from age-course detection and correlations to purified Aβ*56 infusion. The main internal-coherence concern is claim proportionality: the paper’s causal wording about Aβ*56 as the cause or principal cause of Tg2576 memory decline is stronger than the mouse correlation plus rat infusion design directly proves.

Research ConductNoted

The supplied text describes animal behavioral testing, cannula implantation, and intracerebroventricular infusion but does not include an explicit animal ethics approval statement. Competing financial interests are disclosed as present, but the details are linked externally and are treated as an assessability gap rather than a conduct concern.

Flags: 1 declared / 5 total

Reference IntegrityClean

27 of 27 checkable references verified

28 references in manuscript 1 have no canonical index record — counted, but not index-checkable 3 references confirmed by manual review

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordConcern

This paper was retracted on 2024-06-24. See notice: 10.1038/s41586-024-07691-8.

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Alzheimer's disease and other dementias
Type of advanceEmpirical
Route to useSuggested
AdvanceAdvances
BeneficiariesLarge
CitationsFWCI 110.5
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessControlled
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The causal claim is supported by correlation in transgenic mice and a controlled infusion experiment in rats, all under researcher-controlled animal model conditions.

From the paper
“offers the potential for developing precise diagnostic methods to detect its correlate in humans with pre-clinical Alzheimer's disease”

The paper names possible real-world uses of its findings, diagnostics and therapeutic targeting of Ab*, but does not name who would act on them.

Pathway

Drug and diagnostic developers would target or detect the Ab*56 assembly to treat or identify pre-clinical Alzheimer's disease before neurodegeneration.

Barrier

The presence and causal role of Ab*56 in humans with Alzheimer's disease remains unverified, so the mouse and rat findings cannot yet guide clinical products.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Comparing amyloid immunotherapy with cholinesterase inhibitors for Alzheimer's disease

    2026 · Neurology and psychiatry

    Evidence Score
    3.4±0.2
    Reliability
    No concerns
  2. Divergent toxicity mechanisms of amyloid-beta aggregates arising from a single aggregation reaction

    2026 · Basic medicine

    Primary claim

    aggregates enriched during the growth phase downregulated homeostatic microglial markers and induced TLR4-mediated microglial activation, cytokine production, and complement activation, leading to synaptic engulfment and severe disruption of neuronal activity

    Tentative
    Evidence Score
    2.8±0.2
    Reliability
    Caveats
  3. A timeline of tau-mediated synaptotoxicity

    2026 · Basic medicine

    Primary claim

    even brief tau oligomer exposure induces lasting bipartite synapse dysfunction and presenting a timeline of progressive pre- and post-synaptic degeneration.

    Tentative
    Evidence Score
    3.2±0.2
    Reliability
    No concerns

How the rubric works →